2018 Innovation to Commercialization award recipients

The Innovation to Commercialization (I2C) Program is designed to help researchers advance discoveries or inventions towards commercialization by supporting commercialization activities that strengthen the value of their intellectual property, facilitate collaboration and attract future investment.

Now in its second year, MSFHR is pleased to announce eight successful award recipients. These individuals are advancing health innovations that range from new ways to detect prostate cancer, to a novel treatment for inflammatory bowel disease and a wearable exoskeleton to increase the mobility of people with lower limb disabilities.

Researcher
(Host institution)
Project summary Research location
Siamak Arzanpour
SFU
An Advanced Wearable Robotic Exoskeleton for Assisting People with Lower Limb Disabilities (partnered with Rick Hansen Institute) SFU (Surrey)
Jaimie Borisoff
BCIT
AAPLE-Walk: A Novel Gait-Mimicking Exercise Machine for Cardiovascular Fitness and Rehabilitation BCIT
Robert Hancock
UBC
Treatment of Sinusitis UBC 
Dirk Lange
UBC
Novel infection resistant coating for indwelling urinary devices VCHRI
Megan Levings
UBC
Engineered T regulatory cells to treat Crohn's disease BCCHRI
Jessica McAlpine
BC Cancer Agency
Molecular classification for stratification and improved clinical management of endometrial cancers BCCA
David Perrin
UBC
Novel PET Imaging Agents for Prostate Cancer Detection UBC 
Marinko Sarunic
SFU
Cellular Resolution OCT for Clinical Ophthalmology SFU (Burnaby)